SonoThera Raises $125M Series B to Push Nonviral Gene Therapy Into the Clinic
South San Francisco biotechnology company SonoThera has closed a $125M Series B financing led by Vida Ventures, bringing the company's total disclosed funding to approximately $185.75M. The round included participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures, Vivo Capital, ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson Innovation – JJDC, Medical Excellence Capital, RA Capital, and Vertex Ventures HC.
SonoThera is developing ultrasound-mediated, nonviral genetic medicines through its RIPPLE and PORE platforms. The company plans to advance programs targeting Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) toward clinical development, highlighting growing investor interest in solving one of biotechnology's most persistent challenges: delivery.
The broader significance extends beyond a single funding round. The next major advances in genetic medicine may depend less on discovering new payloads and more on finding better ways to get those payloads where they need to go, positioning delivery technologies as one of the industry's most closely watched categories.
What Happened
Biotech funding has become a tougher room to impress. Investors have become increasingly selective, and scientific ambition alone no longer commands premium valuations or oversized rounds. Capital is moving toward platforms, evidence, and technologies capable of supporting multiple therapeutic opportunities, making SonoThera's $125M Series B stand out in an increasingly disciplined market.
The company, led by Dr. Kenneth Greenberg, Co-Founder and CEO, alongside Dr. Michael Davidson, Co-Founder, Dr. Steve Feinstein, Co-Founder, and Carolyne Zimmermann, Chief Business Officer, has built its strategy around a simple observation: gene therapy's biggest challenge may not be what gets delivered. It may be how it gets delivered.
SonoThera's approach combines ultrasound technology with genetic medicine delivery. Through its RIPPLE and PORE platforms, the company aims to enable targeted delivery of DNA and RNA payloads while potentially addressing limitations associated with traditional viral-vector approaches. The capital will support advancement of programs focused on Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease while expanding development of the broader platform. For a company still moving toward clinical-stage execution, this is not just a financing event. It is validation from a syndicate filled with some of healthcare's most experienced investors.
Why This Matters
Gene therapy has spent the better part of 2 decades proving that biology can do extraordinary things. Delivery has spent those same decades reminding everyone that biology does not care how impressive the presentation looked. A therapy can work perfectly in theory and still fail if it cannot safely, efficiently, and repeatedly reach the intended tissue.
That reality has shaped investment decisions across biotechnology. The industry's attention has increasingly shifted toward enabling technologies that improve delivery, manufacturing, safety profiles, and treatment accessibility. Nonviral delivery has become a growing focus because it may address payload-size limitations, redosing constraints, and other challenges associated with viral vectors.
SonoThera sits directly inside that trend. SonoThera's technology is designed around targeted, ultrasound-mediated delivery using a nonviral approach, creating the potential to support multiple disease areas rather than a single therapeutic pathway. That distinction matters because platform companies often create more strategic flexibility than asset-specific companies, generating multiple opportunities while building value around a core technology foundation.
Market Context
The genetic medicine sector has entered a more mature phase. A few years ago, the market rewarded almost any company connected to gene editing, gene therapy, or RNA therapeutics. Capital was abundant, timelines were aggressive, and expectations occasionally bordered on science fiction.
Today, investors ask harder questions. Can the therapy be delivered efficiently? Can it be manufactured at scale? Can patients receive additional doses if needed? Can the platform support multiple indications? Those questions are shaping the next generation of biotech winners.
SonoThera's focus on delivery places it within a growing group of companies attempting to solve foundational infrastructure problems in genetic medicine. While therapeutic headlines often capture public attention, infrastructure innovations frequently determine which technologies eventually reach patients. The South San Francisco biotechnology ecosystem remains one of the most concentrated life sciences hubs in the United States, making it a fitting home for companies pursuing the next wave of genetic medicine innovation.
Competitive Landscape
SonoThera is operating in one of biotechnology's most competitive and technically challenging categories. The broader genetic medicine ecosystem includes companies pursuing viral gene therapies, gene-editing platforms, RNA therapeutics, and next-generation delivery technologies. Each approach attempts to solve different pieces of the same puzzle.
What makes SonoThera distinct is its emphasis on combining ultrasound-mediated delivery with nonviral genetic medicine approaches. The company's preclinical focus spans several major disease areas, including Duchenne muscular dystrophy, autosomal dominant polycystic kidney disease, and Hemophilia A.
Duchenne muscular dystrophy remains one of the most closely watched opportunities in genetic medicine because full-length dystrophin has historically been difficult to deliver using conventional viral approaches. That challenge has created significant interest in alternative delivery technologies. Investors are rarely interested in a technology that works once. They are interested in technologies that work repeatedly across different use cases, which is the strategic lens through which many investors appear to be evaluating SonoThera.
What This Signals
The investor roster may be as important as the funding amount itself. Vida Ventures, ARK Invest, Leaps by Bayer, RA Capital, ARCH Venture Partners, and several other participants have extensive experience evaluating biotechnology opportunities. Groups like these spend enormous amounts of time separating signal from noise.
Their participation suggests confidence not only in SonoThera's scientific direction but also in the broader market opportunity surrounding nonviral delivery systems. It reinforces a larger trend emerging across biotechnology: capital is flowing toward technologies that reduce friction in development, manufacturing, scalability, and therapeutic flexibility.
The future of genetic medicine may ultimately belong to companies that make advanced therapies easier to deliver rather than merely more powerful. That idea sits at the center of why this financing attracted attention well beyond the biotechnology community.
The Bigger Industry Shift
Every technology cycle develops hidden constraints. Artificial intelligence discovered compute constraints, cloud computing encountered infrastructure constraints, and electric vehicles ran into battery constraints. Genetic medicine continues to wrestle with delivery constraints, which is why funding announcements like SonoThera's deserve attention beyond their headline value.
The company is not simply developing treatments for individual diseases. SonoThera is attempting to improve a critical layer of the genetic medicine stack itself, positioning delivery as infrastructure rather than a supporting feature. Whether the company ultimately succeeds will be determined through clinical execution, regulatory progress, and scientific validation.
The financing nevertheless tells us something important today. A growing portion of biotechnology investment is moving toward companies that solve foundational problems rather than isolated symptoms. That shift may define the next decade of genetic medicine as investors continue searching for technologies capable of supporting entire ecosystems rather than single products.
Frequently Asked Questions
What is SonoThera?
SonoThera is a South San Francisco biotechnology company developing ultrasound-mediated, nonviral genetic medicines designed to improve delivery of DNA and RNA therapeutics.
How much funding has SonoThera raised?
SonoThera has raised approximately $185.75M in disclosed funding, including a $125M Series B round announced in 2026.
Who led SonoThera's Series B financing?
Vida Ventures led SonoThera's $125M Series B financing alongside a syndicate of healthcare and life sciences investors.
What diseases is SonoThera targeting?
SonoThera is advancing programs focused on Duchenne muscular dystrophy (DMD), autosomal dominant polycystic kidney disease (ADPKD), and Hemophilia A.
What is SonoThera's RIPPLE platform?
RIPPLE is SonoThera's ultrasound-mediated delivery platform designed to enable targeted delivery of genetic medicines.
What is SonoThera's PORE platform?
PORE is SonoThera's payload engineering platform that supports DNA and RNA therapeutics.
Why is nonviral gene therapy important?
Nonviral gene therapy may address challenges associated with viral vectors, including payload-size limitations and the ability to administer repeat doses.
When does SonoThera expect to enter clinical trials?
SonoThera has stated that it expects to initiate its first clinical trial in Duchenne muscular dystrophy in 2027.
